UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

Respiratory research, 2018-10, Vol.19 (1), p.196-11, Article 196

2018

Volltextzugriff (PDF)

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

BMC pulmonary medicine, 2014-10, Vol.14 (1), p.163-163, Article 163

2014

Volltextzugriff (PDF)

The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants

Annals of the American Thoracic Society, 2018-02, Vol.15 (2), p.200-208

2018

Volltextzugriff (PDF)

Impact and prevention of severe exacerbations of COPD: a review of the evidence

International journal of chronic obstructive pulmonary disease, 2017-01, Vol.12, p.2891-2908

2017

Volltextzugriff (PDF)

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR

ERJ open research, 2017-01, Vol.3 (1), p.73

2017

Volltextzugriff (PDF)

Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2020-09, Vol.202 (5), p.660-671

2020

Volltextzugriff (PDF)

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial

Respiratory research, 2015-06, Vol.16 (1), p.65-65, Article 65

2015

Volltextzugriff (PDF)

Effect of a single exacerbation on decline in lung function in COPD

Respiratory medicine, 2017-07, Vol.128, p.85-91

2017

Volltextzugriff (PDF)

Tiotropium Safety and Performance in Respimat (TIOSPIR) Study: Analysis of Demographic Characteristics and Clinical Outcomes in Patients Enrolled in China Versus Rest of the World

Chest, 2016-04, Vol.149 (4), p.A345-A345

2016

Volltextzugriff (PDF)

Thorax editorial by Jenkins and Beasley related to tiotropium respimat

Thorax, 2013-08, Vol.68 (8), p.782-782

2013

Volltextzugriff (PDF)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study

International journal of chronic obstructive pulmonary disease, 2017-01, Vol.12, p.3391-3405

2017

Volltextzugriff (PDF)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes

Respiratory research, 2015-09, Vol.16 (1), p.107-107, Article 107

2015

Volltextzugriff (PDF)

The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV 1 /FVC Ratio in Tiotropium Safety and Performance in Respimat Participants

Annals of the American Thoracic Society, 2018-02, Vol.15 (2), p.200-208

2018

Volltextzugriff (PDF)

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR ® trial

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.605-616

2018

Volltextzugriff (PDF)

Tiotropium Safety and Performance in Respimat (TIOSPIR) Study: Analysis of Demographic Characteristics and Clinical Outcomes in Patients Enrolled in Asia Countries (Excluding China) Versus Rest of the World

Chest, 2016-04, Vol.149 (4), p.A393-A393

2016

Volltextzugriff (PDF)

Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test

American journal of respiratory and critical care medicine, 2020-05, Vol.201 (9), p.1058-1067

2020

Volltextzugriff (PDF)

Effect of combination treatment on lung volumes and exercise endurance time in COPD

Respiratory medicine, 2012-10, Vol.106 (10), p.1413-1420

2012

Volltextzugriff (PDF)

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.1297-1308

2018

Volltextzugriff (PDF)

Impact of tiotropium on exacerbations versus glycopyrronium and QVA149

Expert review of respiratory medicine, 2015-11, Vol.9 (6), p.675-676

2015

Volltextzugriff (PDF)

Effect of tiotropium on COPD exacerbations: A systematic review

Respiratory medicine, 2016-05, Vol.114, p.1-8

2016

Volltextzugriff (PDF)

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT

Annals of the American Thoracic Society, 2022-02, Vol.19 (2), p.204-213

2022

Volltextzugriff (PDF)

Seasonal Variations in Mortality and Exacerbations in Patients With Chronic Obstructive Pulmonary Disease During the TIOSPIR Trial

Chest, 2014-10, Vol.146 (4), p.66A-66A

2014

Volltextzugriff (PDF)

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease

International journal of chronic obstructive pulmonary disease, 2015-01, Vol.10 (Issue 1), p.549-564

2015

Volltextzugriff (PDF)

Rate of Comorbidities During the 4-Year UPLIFT Trial in COPD: A Post Hoc Analysis

Chest, 2014-10, Vol.146 (4), p.67A-67A

2014

Volltextzugriff (PDF)

Preselection of patients at risk for COPD by two simple screening questions

Respiratory medicine, 2010-07, Vol.104 (7), p.1012-1019

2010

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Respiratory System
(27)
Humans
(26)
Female
(22)
Male
(21)
Chronic Obstructive Pulmonary Disease
(20)
Middle Aged
(19)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(19)
Aged
(18)
Mortality
(14)
Copd
(13)
Pulmonary Disease, Chronic Obstructive - Diagnosis
(13)
Double-Blind Method
(12)
Administration, Inhalation
(11)
Bronchodilator Agents - Adverse Effects
(11)
Bronchodilator Agents - Therapeutic Use
(11)
Patients
(11)
Pulmonary/respiratory
(11)
Treatment Outcome
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial

Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial

The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants

Impact and prevention of severe exacerbations of COPD: a review of the evidence

Discordance in investigator-reported and adjudicated sudden death in TIOSPIR

Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease

Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial

Effect of a single exacerbation on decline in lung function in COPD

Tiotropium Safety and Performance in Respimat (TIOSPIR) Study: Analysis of Demographic Characteristics and Clinical Outcomes in Patients Enrolled in China Versus Rest of the World

Thorax editorial by Jenkins and Beasley related to tiotropium respimat

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes

The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV 1 /FVC Ratio in Tiotropium Safety and Performance in Respimat Participants

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR ® trial

Tiotropium Safety and Performance in Respimat (TIOSPIR) Study: Analysis of Demographic Characteristics and Clinical Outcomes in Patients Enrolled in Asia Countries (Excluding China) Versus Rest of the World

Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test

Effect of combination treatment on lung volumes and exercise endurance time in COPD

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD

Impact of tiotropium on exacerbations versus glycopyrronium and QVA149

Effect of tiotropium on COPD exacerbations: A systematic review

Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT

Seasonal Variations in Mortality and Exacerbations in Patients With Chronic Obstructive Pulmonary Disease During the TIOSPIR Trial

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease

Rate of Comorbidities During the 4-Year UPLIFT Trial in COPD: A Post Hoc Analysis

Preselection of patients at risk for COPD by two simple screening questions

Suchergebnisse filtern